Sitagliptin

This MedLibrary.org supplementary page on Sitagliptin is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:

Related Sponsors

BM Pharmacy Generic pharmaceuticals at unbeatable prices. Insomnia, men's health, hair health, pain control. bmpharmacy.com
Online Pharmacy Carisoprodol, tadalafil, sildenafil, vardenafil and more... xlpharmacy.com
MedBasket.com Discreet. Inexpensive. Fast shipping. Great selection. What more can we say? medbasket.com
Frugalmed 2000 reasons to shop with us first. frugalmed.com
Ads by Tiva

Sitagliptin
Systematic (IUPAC) name
(3R)-3-amino-1-[9-(trifluoromethyl)-
1,4,7,8-tetrazabicyclo[4.3.0]nona-6,8-d ien-4-yl]-
4-(2,4,5-trifluorophenyl)butan-1-one
Identifiers
CAS number 790712-60-6
ATC code A10BH01
PubChem 4369359
Chemical data
Formula C16H15F6N5O 
Mol. mass 407.314 g/mol
Pharmacokinetic data
Bioavailability 87%
Protein binding 38%
Metabolism Hepatic (CYP3A4- and CYP2C8-mediated)
Half life 8 to 14 hours1
Excretion Renal (80%)1
Therapeutic considerations
Licence data

EU, US
Pregnancy cat.

B(US)
Legal status

POM(UK) ℞-only(US)
Routes Oral

Sitagliptin (INN; previously identified as MK-0431, trade name Januvia) is an oral antihyperglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. This enzyme-inhibiting drug is used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a thiazolidinedione) for treatment of diabetes mellitus type 2. The benefit of this medicine is its lower side-effects (e.g., less hypoglycemia, less weight gain) in the control of blood glucose values. Exenatide/Byetta is an alternative drug that also works with the incretin system.

Contents

Adverse effects

In clinical trials, adverse effects were as common with sitagliptin (whether used alone or with metformin or pioglitazone) as they were with placebo, except for nausea and common cold-like symptoms, which were more common with sitagliptin.2 There is no significant difference in the occurrence of hypoglycemia between placebo and sitagliptin.2

History

Sitagliptin was approved by the U.S. Food and Drug Administration (FDA) on October 17, 20063 and is marketed in the US as Januvia by Merck & Co. On April 2, 2007, the FDA approved an oral combination of sitagliptin and metformin marketed in the US as Janumet.

Mechanism

See also: Dipeptidyl peptidase-4 inhibitors

Sitagliptin works to competitively inhibit the enzyme dipeptidyl peptidase 4 (DPP-4). This enzyme breaks down the incretins GLP-1 and GIP, gastrointestinal hormone that are released in response to a meal.4 By preventing GLP-1 and GIP inactivation, GLP-1 and GIP are able to potentiate the secretion of insulin and suppress the release of glucagon by the pancreas. This drives blood glucose levels towards normal. As the blood glucose level approaches normal, the amounts of insulin released and glucagon suppressed diminishes thus tending to prevent an "overshoot" and subsequent low blood sugar (hypoglycemia) which is seen with some other oral hypoglycemic agents.


See also

References

  1. ^ a b Herman G, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang A, Zeng W, Musson D, Winchell G, Davies M, Ramael S, Gottesdiener K, Wagner J (2005). "Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.". Clin Pharmacol Ther 78 (6): 675–88. doi:10.1016/j.clpt.2005.09.002. PMID 16338283. 
  2. ^ a b "Januvia Side Effects & Drug Interactions". RxList.com (2007). Retrieved on 2007-11-28.
  3. ^ U.S. Food and Drug Administration (October 17, 2006). "FDA Approves New Treatment for Diabetes". Press release. Retrieved on 2006-10-17.
  4. ^ Herman G, Bergman A, Liu F, Stevens C, Wang A, Zeng W, Chen L, Snyder K, Hilliard D, Tanen M, Tanaka W, Meehan A, Lasseter K, Dilzer S, Blum R, Wagner J (2006). "Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.". J Clin Pharmacol 46 (8): 876–86. doi:10.1177/0091270006289850. PMID 16855072. 

External links

v • d • e
Oral antidiabetic drugs and Insulin analogs (A10)
Insulin sensitizers
Secretagogues
GLP-1 analog
Alogliptin† · Dutogliptin† · Linagliptin† · Saxagliptin† · Sitagliptin · Vildagliptin
Alpha-glucosidase inhibitors
Amylin analog
Experimental
SGLT2 inhibitor
Insulin analogs
†Undergoing clinical trials. ‡ Withdrawn from market. §Development halted.
v • d • e
Merck & Co., Inc.
Corporate Directors:
Products:
Publications:
Annual Revenue: $22.9 billion USD (▲2% FY 2004) · Employees: 63,000 · Stock Symbol: NYSE: MRK · Website: www.merck.com

Wikipedia content modification information:

  • This page was last modified on 15 November 2008, at 23:17.

Wikipedia Authorship and Review

Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.

Wikipedia Usage Guidelines

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Sitagliptin".

The URL for this specific entry is:

All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.